Loading...
Is the angiotensin receptor–neprilysin inhibitor sacubitril–valsartan superior to the angiotensin-converting–enzyme (ACE) inhibitor ramipril in reducing mortality from acute myocardial infarction (AMI) in patients with left ventricular systolic dysfunction, pulmonary congestion, or both? Researchers addressed this question in the industry-funded, double-blind PARADISE-MI trial (NCT02924727), randomizing 5661 such patients to receive sacubitril–valsartan (97 mg of sacubitril and 103 mg of valsartan twice daily) or ramipril (5 mg twice daily) in addition to recommended therapy.
The average patient age was 64 years, 24% were women, and about 1% were Black. The primary endpoint was death from cardiovascular causes or incident heart failure. The …